Overview of Daratumumab

What is Daratumumab? A Targeted Antibody Therapy

Daratumumab is a specialized biologic medication and the first-in-class treatment that targets the CD38 protein, acting as a highly specific antineoplastic agent to help the body manage conditions characterized by the presence of CD38-expressing malignant cells.

Property	Description
Active ingredient	Daratumumab
Form	Concentrate for solution for infusion; Injectable solution for subcutaneous use
Pharmacological class	Monoclonal Antibody; Targeted Cancer Therapy
Common purpose	To reduce the population of cells expressing the CD38 protein
Origin	Fully Human IgG1kappa Antibody (Recombinant DNA Technology)

What is the Pharmacological Class of Daratumumab?

Daratumumab is a fully human immunoglobulin G1 kappa monoclonal antibody produced using recombinant DNA technology in a mammalian cell line (e.g., Chinese Hamster Ovary). Its high degree of specificity classifies it within the group of targeted cancer therapies. The drug's therapeutic focus is exclusively directed against the CD38 transmembrane glycoprotein, a feature that distinguishes it from non-targeted agents. This distinction is important because the drug was granted breakthrough therapy designation for its role in certain conditions, a status reserved for drugs that demonstrate substantial improvement over existing treatments. Daratumumab is clinically recognized for its efficacy in disease management, indicating the medicine has demonstrated significant clinical benefit in trials.

How Does Daratumumab Identify Target Cells (CD38)?

The fundamental mechanism of Daratumumab is its ability to bind selectively and with high affinity to the CD38 target, functioning as a homing device that marks the harmful cells for destruction. By initiating immune-mediated tumor cell lysis—which involves processes like ADCC and CDC—the medication helps the patient's own immune system recognize and attack the CD38-expressing cell population. Daratumumab exerts its anti-myeloma activity via multiple immune-mediated mechanisms, including the direct induction of apoptosis and immunomodulation. This means that this antibody is designed to utilize several pathways simultaneously to eliminate the targeted cells, which is why it is often used as a foundational therapy in complex treatment plans.

In What Forms and Administration Types is Daratumumab Prepared?

Daratumumab is supplied as an aqueous solution containing the active ingredient and excipients for stability. It is prepared in two principal dosage form(s): as a concentrate for solution for intravenous infusion and, when co-formulated with the enzyme hyaluronidase-fihj, as an injectable solution for subcutaneous use. The addition of the enzyme hyaluronidase to the subcutaneous formulation is a differentiating feature designed to allow for quicker administration times compared to the original intravenous route. These distinct forms offer alternative route of administration options, streamlining the patient experience.

Regulatory References

What side effects are possible with Daratumumab?

Possible Side Effects and Safety Information

The safety profile of Daratumumab is strictly defined by government regulatory documents, classifying adverse reactions by frequency and the body system affected. These classifications highlight the officially documented risks associated with the treatment.

Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions are defined as Very Common (ge 1 in 10 patients) in official prescribing information. These typically include Infusion-Related Reactions (IRRs), which are most frequent during the first administration, and reactions such as fatigue, nausea, diarrhea, constipation, pyrexia (fever), and cough.

Adverse reactions are also classified by the System-Organ Classes (SOC) involved, including Infections and Infestations (e.g., upper respiratory tract infections, pneumonia) and Blood and Lymphatic System Disorders.

Serious Adverse Reactions and Constraints

Official labeling documents emphasize the potential for Serious Infections, including sepsis and pneumonia. The development of Grade 3/4 Cytopenias (severe reductions in blood cell counts, specifically neutropenia and thrombocytopenia) is also a documented serious risk.

A critical safety constraint is the potential for Interference with Serological Testing. Daratumumab's binding properties can cause a false-positive indirect antiglobulin test (Coombs test), which may interfere with blood cross-matching and require specific communication to blood banks. For pregnant individuals, the medicine is not recommended due to the potential for fetal myeloid or lymphoid-cell depletion, and females of reproductive potential must use effective contraception.

Overdose and Emergency Response

The official regulatory documentation for Daratumumab does not specify a unique clinical syndrome for traditional overdose from supra-therapeutic dosing. Instead, the focus of acute toxicity management in the label centers on severe Administration-Related Reactions (ARRs).

Documented Acute Manifestations and Emergency Actions

Classification	Official Regulatory Statement	When to Seek Help
Documented Manifestations	Acute symptoms reported include dyspnea (shortness of breath), hypoxia (low oxygen in the blood), bronchospasm, tachycardia, hypertension, hypotension, fever, and chills.	Symptoms of a severe reaction occurring during or after administration require patients to seek immediate medical attention or get medical help right away, as explicitly directed by the label.
Severe Outcomes	The occurrence of anaphylaxis or a life-threatening Grade 4 reaction has been reported.	Permanent discontinuation of Daratumumab is mandated by regulatory documents for both anaphylactic and life-threatening Grade 4 reactions.

Official Management Requirements

For acute reactions of any severity, the administration must be immediately interrupted, and healthcare professionals must institute appropriate symptomatic and supportive treatment. The medication must be administered in a setting where resuscitation facilities are available. Patients with Light Chain (AL) Amyloidosis and existing cardiac involvement require more frequent monitoring for cardiac adverse reactions due to increased risk, as noted in the regulatory warnings.

Therapeutic Uses of Daratumumab

What Daratumumab treats: main uses and benefits

Daratumumab is a prescription medicine approved to help manage multiple myeloma (MM), a type of cancer affecting plasma cells in the bone marrow, and high-risk smoldering multiple myeloma (HR-SMM), an earlier, asymptomatic stage of the disease. It is utilized in various clinical scenarios to provide therapeutic benefit and support disease management.

It is an approved option for patients with newly diagnosed multiple myeloma and is used in combination with other treatments as part of initial therapy. It also serves as an option for those who have relapsed or refractory multiple myeloma, helping to achieve a clinical response when prior treatments have been tried. For patients with HR-SMM, Daratumumab is used to help reduce the risk of the disease advancing to active multiple myeloma. The overall goal is to help reduce the tumor burden, establish disease control, and ultimately delay disease progression.

Quick Fact: Relief for Disease Progression Daratumumab is utilized to help manage and slow the advancement of multiple myeloma and high-risk smoldering multiple myeloma.

Eligibility and Restrictions for Use

The eligibility for Daratumumab use is strictly defined by regulatory documentation, focusing on patient population, age, and specific health conditions.

Populations for Whom Use is Allowed and Contraindicated

Category	Official Regulatory Status
Populations Allowed	Adult patients (ge 18 years of age) with Multiple Myeloma or High-Risk Smoldering Multiple Myeloma.
Contraindicated Populations	Patients with a history of severe hypersensitivity to the active substance or any formulation component.
Age-Related Eligibility	Use is not recommended in pediatric patients (under 18 years) as safety and effectiveness have not been established. Use in older adults is established.

Condition-Specific Eligibility and Restrictions

Use of Daratumumab is subject to conditions related to organ function and reproductive status:

Pregnancy and Lactation: Use is not recommended during pregnancy, as it may cause fetal harm, or during breastfeeding. Females of reproductive potential must use effective contraception during and for a specified period after treatment.
Organ Impairment: No dose adjustment is necessary for mild to moderate renal impairment. However, use in patients with severe hepatic impairment or those receiving hemodialysis has not been formally studied.

What should I know about interactions with other medicines?

Daratumumab Interactions with other medicines and products

This section describes the officially documented interaction patterns for Daratumumab, strictly as stated in governmental regulatory sources.

Pharmacokinetic Interaction Profile

Daratumumab is a large protein cleared through non-specific catabolism, not through the liver's Cytochrome P450 (CYP) enzyme system or drug transporters. Consequently, regulatory documents state that Daratumumab is not expected to cause pharmacokinetic drug-drug interactions by acting as an inhibitor or inducer of these metabolic pathways. No formal CYP-based interaction studies are documented in major prescribing information.

Pharmacodynamic and Analytical Interactions

Interaction Type	Interacting Substance/Test	Official Outcome/Restriction
Pharmacodynamic	Other Antineoplastic Agents (e.g., Lenalidomide)	Co-administration may increase the risk of documented hematological toxicity (e.g., neutropenia and thrombocytopenia).
Analytical	Pre-transfusion Compatibility Tests (IAT)	Binding to red blood cells causes analytical interference that results in a false positive Indirect Antiglobulin Test (IAT).
Immunological	Live, Attenuated Vaccines	Use is generally not recommended during and following therapy due to the risk in an immunocompromised patient.

Procedural and Timing Requirements

Due to analytical interference, official labeling mandates specific timing rules for blood banking. Patients must be typed and screened for blood compatibility prior to the initiation of Daratumumab therapy. Furthermore, blood banks must be informed that the patient is receiving the medicine to prevent misinterpretation of blood cross-matching results.

Mechanism of Action

CD38 Binding and Multi-Modal Cytotoxicity

Daratumumab selectively binds the CD38 protein, initiating four concurrent cytotoxic mechanisms: Antibody-Dependent Cellular Cytotoxicity (ADCC), Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cellular Phagocytosis (ADCP), and direct apoptosis induction. This multi-pronged attack results in extensive destruction and systemic clearance of the CD38-expressing cell population.

Immunomodulation and T-Cell Environment Alteration

The same binding mechanism causes the depletion of CD38-expressing immunosuppressive cells (like regulatory T cells), thereby modifying immune system suppression. This results in a shift toward an active, effector-driven state, characterized by an increased ratio of cytotoxic T cells, which contributes to an altered host immune response to the target cell population.

Mechanism-Dependent Interference with RBC Testing

As a direct consequence of its specific CD38 binding mechanism, Daratumumab also attaches to the low levels of CD38 present on red blood cells (RBCs). This binding creates an in-vitro laboratory artefact by interfering with blood compatibility tests, presenting an analytical challenge during pre-transfusion compatibility testing.

Dosage and Administration Information

Official Administration and Dosing Guidelines

Daratumumab is administered under the supervision of a healthcare professional in a clinical setting with access to resuscitation facilities. Treatment is structured around highly specific schedules that reduce in frequency over time.

Feature	Official Instruction Summary
Route of Administration	Administered as an Intravenous (IV) infusion or a Subcutaneous (SC) injection.
Dosing Rules	IV Dose: 16 mg/kg actual body weight after dilution in 0.9% Sodium Chloride. SC Dose: Fixed dose of 1,800 mg (co-formulated with hyaluronidase) regardless of patient weight.
Frequency & Schedule	Treatment starts with weekly dosing (Weeks 1-6 or 1-8), transitions to bi-weekly or tri-weekly intervals, and then moves to monthly dosing for long-term maintenance.
Preparation	The IV concentrate must be diluted prior to infusion. The SC injectable solution should not be shaken.
Special Conditions	Pre- and post-administration medications (e.g., corticosteroids, antipyretics, antihistamines) are mandated to be administered with each dose. The first IV dose may be split over two consecutive days (8 mg/kg each day) to shorten the initial infusion time.
Population Rules	No dose adjustment is required for older adults or patients with mild-to-severe renal or mild hepatic impairment. Use in the pediatric population (under 18 years) is not established.
Missed Dose	If a dose is missed, it should be administered as soon as possible, and the schedule must be adjusted to maintain the correct dosing interval.

The use of daratumumab is a structured process that dictates the administration route, precise dosing (weight-based IV versus fixed SC), and a mandatory reduction in treatment frequency over time. This protocol also strictly requires the use of co-medications and professional administration to ensure proper adherence to the labeled usage.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Daratumumab

This section synthesizes the available clinical research, outlining the types of studies that have been conducted, the populations included, and the specific outcomes that researchers have investigated, without stating or implying any results or clinical efficacy.

Evidence for Use in Multiple Myeloma (MM)

Research for Multiple Myeloma (MM) was evaluated in large, multi-center Phase III Randomized Controlled Trials (RCTs). These studies compared treatment regimens that included Daratumumab against other standard combinations for the condition. The study populations included newly diagnosed adults and those with relapsed or refractory disease. Researchers examined several outcomes, including Progression-Free Survival (PFS), Overall Survival (OS), and the rate at which patients achieved a deep response, often measured by Minimal Residual Disease (MRD) negativity.

In trials focused on newly diagnosed MM, both adults considered transplant-eligible and those considered transplant-ineligible (typically older or frailer) was observed in studies. Findings describe patterns in measurements of disease progression or recurrence in the observed populations. For relapsed or refractory MM, studies explored patients who had received differing numbers of previous treatments. Research highlights changes measured during the study period related to the duration of observed responses.

Evidence for Use in High-Risk Smoldering Multiple Myeloma (HR-SMM)

High-Risk Smoldering Multiple Myeloma (HR-SMM) was evaluated in research that included large Phase III RCTs. These studies were specifically designed to compare the treatment regimen against an active monitoring approach (observation) for adults identified as having high-risk SMM. The primary outcome measured was Progression-Free Survival (PFS), specifically defined as the time until the disease progressed to active Multiple Myeloma or death. Studies monitored patterns in the time to disease progression in the observed populations, and also measured the rate at which patients achieved an objective response.

What Remains Uncertain and Areas for Future Research

Evidence highlights what is known — and what is still uncertain — across the research landscape. Research limitations include the fact that data for certain groups remain insufficient, such as for patients who have received numerous prior treatments. Furthermore, patients with severe organ dysfunction (like advanced hepatic impairment) or the most severe cardiac disease were systematically excluded from the main trials, and evidence for these groups is limited. Research provides context but not individual predictions, and studies help show what has been observed so far in the specific conditions under which they were conducted.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Daratumumab (FAQ)

Q: Is Daratumumab considered a type of chemotherapy or something else?

A: According to official product information, Daratumumab is classified as a Monoclonal Antibody and a Targeted Cancer Therapy. This means it is a specialized biologic medicine designed to target a specific protein on the cells. It is not classified as a traditional cytotoxic chemotherapy agent.

Q: What are the most common side effects people report with Daratumumab?

A: Official regulatory documents list several reactions as Very Common (occurring in ≥1 in 10 patients). These most commonly reported effects include Infusion-Related Reactions (IRRs), along with general symptoms like fatigue, nausea, diarrhea, constipation, cough, and fever.

Q: Why is Daratumumab given by infusion instead of a pill?

A: Daratumumab is a large protein, specifically a monoclonal antibody. If taken orally as a pill, the medicine would likely be broken down by stomach acid and the digestive process before it could be absorbed. For this reason, official prescribing information lists the route of administration as either an intravenous infusion or a subcutaneous injection.

Q: Is it common for Daratumumab to affect a person's blood cell counts?

A: Yes, official safety information indicates that the medicine is associated with risks to the Blood and Lymphatic System. This includes the potential for severe reductions in blood cell counts, specifically categorized as Grade 3/4 Cytopenias.

Q: Is Daratumumab typically used alone or in combination with other treatments?

A: Official drug labeling indicates that Daratumumab is approved for use in two primary modes. It can be used as monotherapy (used by itself) or in combination with other antineoplastic agents, depending on the specific condition it is treating.

Q: Has Daratumumab been studied in people who have liver or kidney issues?

A: Regulatory information indicates that no dose adjustment is required for patients with mild-to-severe renal impairment or mild hepatic impairment. However, official studies have not formally examined the use of Daratumumab in patients with severe hepatic impairment (advanced liver issues).

Q: Does the mechanism of Daratumumab weaken the entire immune system?

A: While the drug's mechanism is complex, official documentation notes risks associated with a reduced immune defense. This includes the potential for Serious Infections, such as pneumonia and sepsis, which suggests the immune system’s ability to fight off infection is reduced during treatment.

Q: What evidence exists for Daratumumab being used in combination with steroid medicines?

A: Steroid medicines, such as corticosteroids, serve two distinct roles described in official documentation. They are mandated as pre- and post-administration medications to help reduce potential infusion-related reactions, and they are also frequently used as a therapeutic component in many approved combination treatment regimens.

Q: Are there different versions or formulations of Daratumumab currently available?

A: Yes, according to official prescribing information, Daratumumab is available in two principal forms: a concentrate for intravenous (IV) infusion and an injectable solution for subcutaneous (SC) use. The subcutaneous formulation is prepared with an enzyme called hyaluronidase.

Q: How does the administration of Daratumumab compare to older treatments for the same condition?

A: The development of the subcutaneous (SC) injection is recognized as a key difference. Official regulatory summaries note that the SC injection allows for significantly shorter administration times (about 3 to 5 minutes for the injection itself) compared to the initial intravenous (IV) infusion, which can take several hours.

Q: Why is a specific set of blood tests typically required before starting Daratumumab?

A: Official documentation mandates that blood compatibility tests, such as typing and screening, must be performed prior to the start of therapy. This is required because the drug can bind to red blood cells and cause an analytical interference that results in a false-positive blood compatibility test, making blood matching difficult later on.

Q: What is the main reason doctors prescribe Daratumumab?

A: Daratumumab is officially prescribed for the treatment of certain conditions, primarily Multiple Myeloma and High-Risk Smoldering Multiple Myeloma. The goal is typically to achieve disease control, deepen patient response to therapy, and extend the time before the condition progresses.

Q: How is Daratumumab different from a standard drug treatment?

A: Daratumumab is classified as a highly specific Monoclonal Antibody. It works by selectively targeting the CD38 protein on the surface of cells, using multiple immune-mediated mechanisms to achieve its effect. This selective action distinguishes it from non-targeted treatments.

Q: Does Daratumumab treat just one type of disease?

A: Official regulatory approval is granted for the treatment of Multiple Myeloma (MM) and High-Risk Smoldering Multiple Myeloma (HR-SMM). While these conditions are related, they are considered two distinct diseases covered by the labeling.

Q: How long does a typical Daratumumab infusion take?

A: According to official administration instructions, the duration depends on the method. The initial intravenous (IV) infusion typically takes about 7 hours, although this can sometimes be split over two days. Subsequent IV infusions are usually shorter, lasting between 3 and 5 hours, and the subcutaneous injection takes only about 3 to 5 minutes.

Q: Can Daratumumab interact with over-the-counter pain relievers?

A: Regulatory information states that Daratumumab is a large protein and is not expected to cause pharmacokinetic drug-drug interactions via the liver's main enzyme system. However, patients are often given common pain relievers like acetaminophen as a mandated premedication before the infusion.

Q: Are there any foods or drinks officially listed to avoid while using Daratumumab?

A: Official regulatory prescribing information provides details on interactions with other medicines and tests, but no formal interactions between Daratumumab and specific foods or drinks are documented that require avoidance.

Q: Is it possible to receive Daratumumab outside of a hospital setting?

A: Official instructions mandate that the administration must occur in a clinical setting under the supervision of a qualified healthcare professional. This administration setting ensures that immediate access to necessary equipment is available to safely manage potential infusion reactions, as mandated by official instructions.

Q: Does Daratumumab have a widely recognized generic name?

A: The active ingredient name, daratumumab, is the official non-proprietary or generic name for the antibody. This is the name used in regulatory and medical literature globally.

Q: Does Daratumumab cause hair loss or changes to skin and nails?

A: Official safety documentation notes that hair loss (alopecia) is not listed as a common or serious adverse reaction. However, skin reactions are documented, including rash and localized injection-site reactions like redness or bruising, particularly with the subcutaneous formulation.

Q: How new is Daratumumab? When was it first made available?

A: Daratumumab is a relatively newer biologic treatment. The initial intravenous formulation was first approved by the FDA in November 2015 for certain indications in Multiple Myeloma.

Q: Does Daratumumab interact with common herbal supplements like St. John's Wort?

A: Regulatory documents indicate that Daratumumab is not expected to cause pharmacokinetic drug-drug interactions via the main liver enzyme system. Furthermore, no specific interactions with common herbal supplements are documented in the official prescribing information.

Q: Can Daratumumab cause noticeable changes in skin appearance or rashes?

A: Yes, official safety documentation lists rash as a potential side effect. Localized injection-site reactions, such as redness or bruising, are also possible, particularly with the subcutaneous administration.

Q: Can Daratumumab affect vision or eye health?

A: Official safety information indicates that symptoms such as blurred vision and eye pain have been reported. These can be associated with serious Infusion-Related Reactions (IRRs).

Q: Is it generally safe to drive or operate machinery after a Daratumumab treatment?

A: Due to potential side effects like dizziness and fatigue, regulatory guidance indicates that caution should be exercised when driving or operating machinery until the individual knows how the medicine affects them.

Q: What evidence is there about quality of life themes during Daratumumab treatment?

A: Clinical studies referenced in regulatory decision summaries often include specific endpoints related to Health-Related Quality of Life (HRQoL). Data from these trials has been reported as showing preserved or improving trends in quality of life during treatment.

How should Daratumumab be stored and disposed of?

Storage and Disposal Requirements for Daratumumab

The storage of daratumumab, for both the intravenous concentrate and the subcutaneous injection, is governed by mandatory regulatory requirements to maintain product stability.

Official Storage Conditions

Condition	Requirement
Temperature Range	Store unopened containers in a refrigerator between 2 C and 8 C (36 F to 46 F).
Protection	Store in the original carton to protect the contents from light.
Prohibitions	Do not freeze the product. Do not shake the vial or container.
Child Safety	Keep the medicine out of the reach of children.

Stability and Disposal

Once prepared, the stability of the solution is limited. The diluted intravenous solution may be stored for up to 24 hours under refrigeration, but the final infusion must be completed within 12 to 15 hours after being removed from the refrigerator. Any unused product, waste material, or expired medicine must be disposed of in accordance with local pharmaceutical waste requirements.

Daratumumab